Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) Short Interest Update

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTWGet Free Report) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 11,900 shares, a decrease of 15.6% from the February 29th total of 14,100 shares. Based on an average daily trading volume, of 6,300 shares, the days-to-cover ratio is presently 1.9 days.

Rocket Pharmaceuticals Stock Performance

Shares of RCKTW stock opened at $0.30 on Friday. The firm’s 50 day moving average is $0.29 and its 200 day moving average is $0.30. Rocket Pharmaceuticals has a 12 month low of $0.06 and a 12 month high of $0.50.

Institutional Trading of Rocket Pharmaceuticals

A hedge fund recently bought a new stake in Rocket Pharmaceuticals stock. Boothbay Fund Management LLC bought a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTWFree Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 240,233 shares of the company’s stock, valued at approximately $4,773,000.

About Rocket Pharmaceuticals

(Get Free Report)

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

Recommended Stories

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.